Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of artesunate-pyronaridine versus artemether-lumefantrine for uncomplicated falciparum malaria in Ugandan children
PACTR202509595165365Phase 4Not yet recruiting
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of artesunate, pyronaridine, artemether and lumefantrine in malaria and Malaria (2 arms). Primary endpoint: 42-day cure rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
artesunatepyronaridineartemetherlumefantrine
03
Conditions
malariaMalaria
Beyond the preview
Go deeper on PACTR202509595165365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509595165365.